7:25 am LA Jolla Pharma shares spike 63% following positive Phase 2 Kidney disease trail results
La Jolla Pharm (LJPC $17.84 +6.94) announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease (:CKD).
The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. Specifically, a dose of 1.5 mg/m2 led to a statistically significant (p=0.045) increase in estimated glomerular filtration rate (eGFR) compared to placebo between baseline and end of treatment. At the 30 …More